Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic dev ....
Read MoreEnterprises can sometimes use as little as 1% of their total available compute due to the 'Memory Wall' bottleneck and other systems design inefficien ....
Read More